Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades. The findings could lead to a better ...
Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results